Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 IN PLASTIC CONTAINER versus AMINOSYN II 5 IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 IN PLASTIC CONTAINER versus AMINOSYN II 5 IN DEXTROSE 25 IN PLASTIC CONTAINER.
AMINOSYN II 3.5% IN PLASTIC CONTAINER vs AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 3.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis and maintenance of nitrogen balance. The amino acids serve as substrates for protein synthesis, and their metabolism yields nitrogen for ureagenesis and carbon skeletons for gluconeogenesis or oxidation.
Amino acids serve as substrates for protein synthesis and nitrogen balance; dextrose provides caloric energy. Dextrose stimulates insulin release, promoting cellular uptake of amino acids.
Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 mL/kg/hour (equivalent to 0.035-0.07 g amino acids/kg/hour) for protein supplementation, not to exceed 0.2 g nitrogen/kg/day. Dosage individualized based on metabolic needs and clinical response.
Intravenous administration based on protein requirements: 1.0-2.0 g/kg/day amino acids, corresponding to 20-40 mL/kg/day of AMINOSYN II 5% in DEXTROSE 25%. Typical adult dose starts at 30-40 mL/hour, titrated to metabolic goals.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is not typically defined as a single value because they are rapidly cleared from plasma for protein synthesis and metabolic processes. For labeled amino acids, the plasma clearance half-life ranges from 10-30 minutes. Clinically, the half-life is short; continuous infusion is required to maintain plasma amino acid levels. In patients with hepatic or renal dysfunction, half-life may be prolonged.
Not applicable as a single entity; amino acids have rapid plasma clearance (t1/2 of minutes to hours) and dextrose is rapidly cleared (t1/2 ~1-2 hours). Clinical context: Continuous infusion maintains steady state.
Aminosyn II 3.5% is a crystalline amino acid solution. The amino acids are metabolized and utilized for protein synthesis. Excess nitrogen is converted to urea in the liver and excreted renally as urea. Approximately 80-90% of infused amino acids are incorporated into proteins or metabolized; the remainder is excreted in urine as urea and other nitrogenous wastes. Fecal excretion is negligible (less than 2%) as amino acids are not significantly eliminated in bile. In patients with renal impairment, urea excretion is decreased, leading to azotemia.
Amino acids are primarily metabolized; nitrogen is excreted as urea (renal, ~85%) and ammonia (renal, ~2-5%); glucose is fully metabolized to CO2 and water (exhaled and renal); electrolytes are excreted renally. Less than 5% excreted unchanged renally.
Category C
Category C
Amino Acid Solution
Amino Acid Solution